[CAS NO. 64953-12-4] Moxalactam sodium salt
PRODUCTS SPECIFICATIONS [64953-12-4]
DESCRIPTION [64953-12-4]
Overview
| MDL | MFCD03427565 |
|---|---|
| Molecular Weight | 564.44 |
| Molecular Formula | C20H18N6Na2O9S |
| SMILES | O=C(C(N12)=C(CSC3=NN=NN3C)CO[C@]2([H])[C@](OC)(NC([C@H](C(O[Na])=O)C4=CC=C(O)C=C4)=O)C1=O)O[Na] |
1 Publications Citing Use of MCE
Summary
Moxalactam (Latamoxef) sodium salt is a synthetic oxa-β-lactam antibiotic . Moxalactam sodium salt has a broad spectrum of activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria . Moxalactam sodium salt inhibits production of β-lactamases [1] .
IC50 & Target
β-lactamases [1]
In Vitro
Moxalactam (Latamoxef) inhibits 90% of strains of
Escherichia coli
,
Klebsiella
species,
Proteus
species,
Morganella morganii
,
Neisseria gonorrhoeae
,
Neisseria meningitidis
,
Haemophilus influenzae
and
Salmonella
species, including strains which are resistant to
Cephalothin
(HY-B1275A) and
Gentamicin
(HY-A0276A) at concentrations of less than 1 μg/mL
[1]
.
Moxalactam exhibits moderate activity against
P. aeruginosa
and is usually active against other species of Pseudomonas,
Acinetobacter
species are usually resistant to Moxalactam
[1]
.
Moxalactam has marked stability in vitro against a variety of β-lactamases, including that produced by
B. fragilis
, inhibits production of β-lactamases and does not induce class I β-lactamase
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Moxalactam (Latamoxef) (0-7.4 mg/mouse; s.c.; once) is effective against bacterial infections in mice [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Four-week-old male strain ICR mice, weighing 18-20 g, bacterial infection model [2] |
| Dosage: | 0-7.4 mg/mouse |
| Administration: | Subcutaneous injection, once |
| Result: | Showed protective activity with ED 50 s less than 7.4 mg/mouse against gram-positive and gram-negative bacteria infected mice. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Solvent & Solubility
H 2 O : 100 mg/mL ( 177.17 mM ; Need ultrasonic)
DMSO : 62.5 mg/mL ( 110.73 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.7717 mL | 8.8583 mL | 17.7167 mL |
| 5 mM | 0.3543 mL | 1.7717 mL | 3.5433 mL |
| 10 mM | 0.1772 mL | 0.8858 mL | 1.7717 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 130 mg/mL (230.32 mM); Clear solution; Need ultrasonic
-
2.
-
3.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (3.69 mM); Clear solution
References
- [1] Carmine AA, et al. Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1983 Oct;26(4):279-333.
- [2] Goto S. In vitro and in vivo antibacterial activity of moxalactam, an oxa-β-lactam antibiotic. Clinical Infectious Diseases, 1982, 4(Supplement_3): S501-S510.
Synonyms